Case Report and Genomic Analysis of Cefiderocol-Resistant Escherichia coli Clinical Isolates.


Journal

American journal of clinical pathology
ISSN: 1943-7722
Titre abrégé: Am J Clin Pathol
Pays: England
ID NLM: 0370470

Informations de publication

Date de publication:
03 Feb 2022
Historique:
received: 13 04 2021
accepted: 01 06 2021
pubmed: 21 9 2021
medline: 11 3 2022
entrez: 20 9 2021
Statut: ppublish

Résumé

Cefiderocol is a novel siderophore cephalosporin with in vitro activity against multidrug-resistant (MDR), gram-negative bacteria and intrinsic structural stability to all classes of carbapenemases. We sought to identify gene variants that could affect the mechanism of action (MOA) of cefiderocol. We report a case of bacteremia in a liver transplant candidate with a strain of carbapenem-resistant Escherichia coli that was found to be resistant to cefiderocol despite no prior treatment with this antimicrobial agent. Using whole-genome sequencing, we characterized the genomic content of this E coli isolate and assessed for genetic variants between related strains that were found to be cefiderocol susceptible. We identified several variants in genes with the potential to affect the mechanism of action of cefiderocol. The cefiderocol resistance in the E coli isolate identified in this study is likely due to mutations in the cirA gene, an iron transporter gene.

Identifiants

pubmed: 34542575
pii: 6372662
doi: 10.1093/ajcp/aqab115
doi:

Substances chimiques

Anti-Bacterial Agents 0
Cephalosporins 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

257-265

Informations de copyright

© American Society for Clinical Pathology, 2021. All rights reserved.For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Travis K Price (TK)

Department of Pathology and Laboratory Medicine, Los Angeles, CA, USA.

Kusha Davar (K)

Division of Infectious Disease, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Deisy Contreras (D)

Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Kevin W Ward (KW)

Department of Pathology and Laboratory Medicine, Los Angeles, CA, USA.

Omai B Garner (OB)

Department of Pathology and Laboratory Medicine, Los Angeles, CA, USA.

Patricia J Simner (PJ)

Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Shangxin Yang (S)

Department of Pathology and Laboratory Medicine, Los Angeles, CA, USA.

Sukantha Chandrasekaran (S)

Department of Pathology and Laboratory Medicine, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH